Pyrotinib - Jiangsu Hengrui Medicine

Drug Profile

Pyrotinib - Jiangsu Hengrui Medicine

Alternative Names: BLTN; Pyrroltinib maleate

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Hengrui Pharmaceutical
  • Developer Jiangsu Hengrui Medicine Co.; Tongji University
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Non-small cell lung cancer
  • Phase I Gastric cancer

Most Recent Events

  • 05 Dec 2017 Efficacy and adverse events data from a phase I/II trial in Breast cancer presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS-2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastric-cancer(Late-stage disease) in China (PO)
  • 17 Mar 2017 Jiangsu HengRui Medicine Co plans a phase III trial for Breast cancer(Metastatic disease, Combination therapy, Second-line therapy or greater) in China (NCT03080805)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top